Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Henrik Lövborg:

Increased Risk of Drug-Induced Hyponatremia during High Temperatures. Jönsson AK et al. Int J Environ Res Public Health. (2017)

The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting. Karlsson SA et al. Eur J Clin Pharmacol. (2015)

[The new cancer drugs should be administered with individualized dosage]. Peterson C et al. Lakartidningen. (2016)

Search results

Items: 1 to 20 of 24

1.

Increased Risk of Drug-Induced Hyponatremia during High Temperatures.

Jönsson AK, Lövborg H, Lohr W, Ekman B, Rocklöv J.

Int J Environ Res Public Health. 2017 Jul 22;14(7). pii: E827. doi: 10.3390/ijerph14070827.

2.

[The new cancer drugs should be administered with individualized dosage].

Peterson C, Lövborg H.

Lakartidningen. 2016 Dec 8;113. pii: EAA7. Swedish. No abstract available.

3.

The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.

Karlsson SA, Jacobsson I, Boman MD, Hakkarainen KM, Lövborg H, Hägg S, Jönsson AK.

Eur J Clin Pharmacol. 2015 May;71(5):631-6. doi: 10.1007/s00228-015-1839-6. Epub 2015 Apr 7.

4.

Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system.

Lövborg H, Holmlund M, Hägg S.

BMC Pharmacol Toxicol. 2014 Jun 9;15:31. doi: 10.1186/2050-6511-15-31.

5.

A fatal outcome after unintentional overdosing of rivastigmine patches.

Lövborg H, Jönsson AK, Hägg S.

Curr Drug Saf. 2012 Feb;7(1):30-2.

6.

A prospective analysis of the preventability of adverse drug reactions reported in Sweden.

Lövborg H, Eriksson LR, Jönsson AK, Bradley T, Hägg S.

Eur J Clin Pharmacol. 2012 Aug;68(8):1183-9. doi: 10.1007/s00228-012-1237-2. Epub 2012 Feb 19.

PMID:
22349466
7.

[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value].

Lövborg H, Jacobsson I, Hägg S.

Lakartidningen. 2009 Nov 4-12;106(45):2968-9. Swedish. No abstract available.

PMID:
19998819
8.

Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug.

Lövborg H, Burman R, Gullbo J.

BMC Res Notes. 2009 Jun 29;2:114. doi: 10.1186/1756-0500-2-114.

9.

Utilization of a right-handed coiled-coil protein from archaebacterium Staphylothermus marinus as a carrier for cisplatin.

Eriksson M, Hassan S, Larsson R, Linder S, Ramqvist T, Lövborg H, Vikinge T, Figgemeier E, Müller J, Stetefeld J, Dalianis T, Ozbek S.

Anticancer Res. 2009 Jan;29(1):11-8.

10.

The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.

Wickström M, Johnsen JI, Ponthan F, Segerström L, Sveinbjörnsson B, Lindskog M, Lövborg H, Viktorsson K, Lewensohn R, Kogner P, Larsson R, Gullbo J.

Mol Cancer Ther. 2007 Sep;6(9):2409-17.

11.

Mechanism of action of cytotoxic cyclotides: cycloviolacin O2 disrupts lipid membranes.

Svangård E, Burman R, Gunasekera S, Lövborg H, Gullbo J, Göransson U.

J Nat Prod. 2007 Apr;70(4):643-7. Epub 2007 Mar 23.

PMID:
17378610
12.

Image-based screening for the identification of novel proteasome inhibitors.

Rickardson L, Wickström M, Larsson R, Lövborg H.

J Biomol Screen. 2007 Mar;12(2):203-10. Epub 2007 Jan 4.

PMID:
17208922
13.

CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome.

Hassan SB, Lövborg H, Lindhagen E, Karlsson MO, Larsson R.

Anticancer Res. 2006 Nov-Dec;26(6B):4431-6.

14.

Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.

Larsson DE, Lövborg H, Rickardson L, Larsson R, Oberg K, Granberg D.

Anticancer Res. 2006 Nov-Dec;26(6B):4125-9.

15.

Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.

Wickström M, Danielsson K, Rickardson L, Gullbo J, Nygren P, Isaksson A, Larsson R, Lövborg H.

Biochem Pharmacol. 2007 Jan 1;73(1):25-33. Epub 2006 Aug 26.

PMID:
17026967
16.

Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.

Fryknäs M, Rickardson L, Wickström M, Dhar S, Lövborg H, Gullbo J, Nygren P, Gustafsson MG, Isaksson A, Larsson R.

J Biomol Screen. 2006 Aug;11(5):457-68.

PMID:
16928983
17.

Screening of an annotated compound library for drug activity in a resistant myeloma cell line.

Rickardson L, Fryknäs M, Haglund C, Lövborg H, Nygren P, Gustafsson MG, Isaksson A, Larsson R.

Cancer Chemother Pharmacol. 2006 Dec;58(6):749-58. Epub 2006 Mar 10.

PMID:
16528529
18.

Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.

Lövborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R.

Int J Cancer. 2006 Mar 15;118(6):1577-80.

19.

Screening for apoptosis--classical and emerging techniques.

Lövborg H, Gullbo J, Larsson R.

Anticancer Drugs. 2005 Jul;16(6):593-9. Review.

PMID:
15930885
20.

Supplemental Content

Loading ...
Support Center